Marcus Schindler speaking at ELRIG Drug Discovery 2024 in London, UK. Credit: Jenna Philpott / GlobalData. Chronic diseases such as obesity are as urgent as global warming and climate change, according to Novo Nordisk’s chief scientific officer (CSO) Marcus Schindler. […]
Chronic diseases “as urgent as climate change,” says Novo Nordisk CSO Read More »
Martin Redhead presenting at the ELRIG Drug Discovery 2024 conference in London, UK. Credit: Jenna Philpott / GlobalData. As AI continues to disrupt the healthcare industry, more pharma companies are using algorithms to design drug molecules. AI-driven pharma tech company
Exscientia outline robot and AI use in drug discovery workflow Read More »
Roche announced the agreement at its annual pharma day in London, UK. Image shows Roche’s head office in California, USA. Credit: Michael Vi via Shutterstock. Genentech is strengthening its oncology pipeline by acquiring Regor Pharmaceuticals’ portfolio of breast cancer cyclin-dependent
Genentech buys Regor’s CDK inhibitors in $850m deal Read More »
A study presented at ESMO 2024 showed that cancer patients vaccinated with the Covid-19 mRNA vaccine had better survival outcomes whilst taking immune checkpoint inhibitors. Credit: Yuganov Konstantin via Shutterstock. A retrospective analysis of patients with advanced lung cancer revealed
mRNA Covid-19 vaccines may boost cancer immunotherapy effectiveness Read More »
Cobenfy introduces a new mechanism of action to the schizophrenia treatment landscape and an additional option for patients. Credit: 13_Phunkod via Shutterstock. The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s first-in-class schizophrenia drug Cobenfy (xanomeline-trospium), providing
BMS wins approval for schizophrenia drug acquired from Karuna Read More »
The panel at HETT 2024 discussing how the new government can transform health and care. Credit: Jenna Philpott / GlobalData. The UK’s newly formed Labour government has faced a critical month in addressing the nation’s healthcare challenges. On 12 September,
How can the UK’s Labour government transform health and care? Read More »
The acquisition expands Telix’s North American manufacturing footprint. Credit: Pixels Hunter via Shutterstock. Telix Pharmaceuticals has bought US-based radioisotope manufacturer RLS Radiopharmacies to expand its manufacturing footprint in the US. The acquisition will cost the Australian radiopharma company $230m upfront,
Telix acquires RLS Radiopharmacies to expand US manufacturing presence Read More »
